Advanced Biomedical Research

A comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesis

Authors

1 Department of Physiology, Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Biochemistry, Payame Noor University, Tehran, Iran

3 Department of Basic Sciences, Isfahan Payame Noor University, Isfahan, Iran

Abstract

Background : There are controversial reports about the antiangiogenic effects of peroxisome proliferator-activated receptor α (PPARα). In the current study, we compared the effects of PPARα agonist and antagonist on human umbilical vein endothelial cells (HUVECs) angiogenesis with matrigel assay.
Materials and Methods : HUVECs (1 × 10 5 cells/well) treated with PPARα agonist (fenofibrate) and antagonist (GW6471) were cultured on matrigel for 24 h. Treated cells were stained with calcein and investigated by fluorescent microscopy. The obtained images were also analyzed by AngioQuant software. Finally, the data were analyzed using SPSS 15 software, Kruskal-Wallis and one way ANOVA.
Results: Statistical analysis showed that fenofibrate significantly inhibit the tube formation (size, length, junction) (P < 0.05) but there was a trend to increased angiogenesis in GW6471 treated group (P > 0.05).
Conclusion: These results showed that PPARα agonist is effective in suppression of angiogenesis. Further studies are needed to confirm these results in in vivo studies.

Keywords

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.  Back to cited text no. 1
[PUBMED]    
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.  Back to cited text no. 2
[PUBMED]    
3. Margeli A, Kouraklis G, Theocharis S. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 2003;6:165-9.  Back to cited text no. 3
[PUBMED]    
4. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-76.  Back to cited text no. 4
[PUBMED]    
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.  Back to cited text no. 5
[PUBMED]    
6. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16:2-14.  Back to cited text no. 6
[PUBMED]    
7. Singh RP, Agarwal R. Tumor angiogenesis: A potential target in cancer control by phytochemicals. Curr Cancer Drug Targets 2003;3:205-17.  Back to cited text no. 7
[PUBMED]    
8. Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000;14:2373-6.  Back to cited text no. 8
[PUBMED]    
9. Pozzi A, Capdevila JH. PPARα ligands as antitumorigenic and antiangiogenic agents. PPAR Res 2008;2008:906542  Back to cited text no. 9
    
10. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: Metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87-98.  Back to cited text no. 10
[PUBMED]    
11. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2. J Biol Chem 1999;274:17042-8.  Back to cited text no. 11
[PUBMED]    
12. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999;19:2094-104.  Back to cited text no. 12
[PUBMED]    
13. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, et al. Role for peroxisome proliferator-activated receptor α in oxidized phospholipidinduced synthesis of monocyte chemotactic protein-1 interleukin-8 by endothelial cells. Circ Res 2000;87:516-21.  Back to cited text no. 13
[PUBMED]    
14. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999;19:546-51.  Back to cited text no. 14
[PUBMED]    
15. Theocharis S, Margeli A, Vielh P, Kouraklis G. "Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators." Cancer Treat Rev 2004;30:545-54.  Back to cited text no. 15
    
16. Roberts RA, Chevalier S, Hasmall SC, James NH, Cosulich SC, Macdonald N. PPARα and the regulation of cell division and apoptosis. Toxicology 2002;182:167-70.  Back to cited text no. 16
    
17. G iaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptor-ã ligands: Potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer. PPAR Res 2008;2008:431763.  Back to cited text no. 17
    
18. Y asui Y, Kim M, Tanaka T. PPAR ligands for cancer chemoprevention. PPAR Res 2008;2008:548919.  Back to cited text no. 18
    
19. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002;293:1431-7.  Back to cited text no. 19
[PUBMED]    
20. Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 2003;60:810-9.  Back to cited text no. 20
[PUBMED]    
21. Meissner M, Stein M, Urbich C, Reisinger K, Suske G, Staels B, et al. PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 2004;94:324-32.  Back to cited text no. 21
[PUBMED]    
22. Kasai T, Miyauchi K, Yokoyama T, Aihara K, Daida H. Efficacy of peroxisome proliferative activated receptor (PPAR)-α ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis 2006;188:274-80.  Back to cited text no. 22
[PUBMED]    
23. Blann AD, Belgore FM, Constans J, Conri C, Lip GY. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001;87:1160-3.  Back to cited text no. 23
[PUBMED]    
24. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, et al. Selective activation of peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008;57:1394-404.  Back to cited text no. 24
    
25. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998;111:3621-31.  Back to cited text no. 25
[PUBMED]    
26. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.  Back to cited text no. 26
[PUBMED]    
27. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnés CM, Fannon M, et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 2008;105:985-90.  Back to cited text no. 27
    
28. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: An emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010;6:454-63.  Back to cited text no. 28
[PUBMED]    
29. Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009;105:114-27.  Back to cited text no. 29
[PUBMED]    
Advanced Biomedical Research
Volume 2013, July
July 2013
Pages 1-5